Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

NCT03544099 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class

Stopped Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

Conditions

Interventions

Sponsor

National Health Research Institutes, Taiwan

Collaborators